See more : Skillsoft Corp. (SKIL) Income Statement Analysis – Financial Results
Complete financial analysis of Vor Biopharma Inc. (VOR) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Vor Biopharma Inc., a leading company in the Biotechnology industry within the Healthcare sector.
- Kimberly-Clark Corporation (KMY.DE) Income Statement Analysis – Financial Results
- BioInvent International AB (publ) (BINV.ST) Income Statement Analysis – Financial Results
- Diamond Lake Minerals, Inc. (DLMI) Income Statement Analysis – Financial Results
- Globaltrans Investment Plc (GLTR.ME) Income Statement Analysis – Financial Results
- GitLab Inc. (GTLB) Income Statement Analysis – Financial Results
Vor Biopharma Inc. (VOR)
About Vor Biopharma Inc.
Vor Biopharma, Inc., a clinical-stage company, develops engineered hematopoietic stem cell (eHSC) therapies for cancer patients. It is developing VOR33, an eHSC product candidate that is in phase 1/2 to treat acute myeloid leukemia (AML) and other hematological malignancies. The company's VOR33 eHSCs lacks CD33, a protein that is expressed by AML blood cancer cells. The company's eHSCs targeted therapies, such as CAR-Ts, bispecific antibodies, and antibody-drug conjugates provide treatment for blood cancers. Vor Biopharma, Inc. has a collaboration agreement with Akron BioProducts to develop and manufacture cGMP nucleases. The company was incorporated in 2015 and is headquartered in Cambridge, Massachusetts.
Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 |
---|---|---|---|---|---|---|
Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Cost of Revenue | 3.49M | 8.96M | 4.45M | 1.39M | 91.00K | 20.00K |
Gross Profit | -3.49M | -8.96M | -4.45M | -1.39M | -91.00K | -20.00K |
Gross Profit Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
Research & Development | 94.32M | 64.55M | 47.53M | 31.62M | 6.20M | 2.43M |
General & Administrative | 31.72M | 28.87M | 21.49M | 11.75M | 4.22M | 427.00K |
Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
SG&A | 31.72M | 28.87M | 21.49M | 11.75M | 4.22M | 427.00K |
Other Expenses | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Operating Expenses | 126.04M | 93.42M | 69.02M | 43.37M | 10.42M | 2.86M |
Cost & Expenses | 126.04M | 93.42M | 69.02M | 43.37M | 10.42M | 2.86M |
Interest Income | 8.17M | 1.32M | 119.00K | 29.00K | 154.00K | 0.00 |
Interest Expense | 0.00 | 0.00 | 0.00 | 0.00 | 608.00K | 1.00M |
Depreciation & Amortization | 3.49M | 8.96M | 4.45M | 1.39M | 91.00K | 20.00K |
EBITDA | -114.37M | -90.89M | -67.58M | -41.95M | -10.17M | -2.84M |
EBITDA Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
Operating Income | -126.04M | -93.42M | -69.02M | -43.37M | -10.42M | -2.86M |
Operating Income Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
Total Other Income/Expenses | 8.17M | 1.32M | 119.00K | 29.00K | -422.00K | -1.29M |
Income Before Tax | -117.86M | -92.09M | -68.90M | -43.34M | -10.84M | -4.15M |
Income Before Tax Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
Income Tax Expense | 0.00 | -1.32M | -119.00K | 427.70K | 608.00K | -289.00K |
Net Income | -117.86M | -90.77M | -68.78M | -43.34M | -11.45M | -4.15M |
Net Income Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
EPS | -1.75 | -2.29 | -1.85 | -1.17 | -0.31 | -0.73 |
EPS Diluted | -1.75 | -2.29 | -1.85 | -1.17 | -0.31 | -0.73 |
Weighted Avg Shares Out | 67.19M | 39.55M | 37.17M | 37.13M | 37.12M | 5.66M |
Weighted Avg Shares Out (Dil) | 67.19M | 39.55M | 37.17M | 37.13M | 37.12M | 5.66M |
Vor Bio Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
Vor Bio (VOR) Up on Positive Update From AML Cell Therapy Study
Vor Bio Doses First AML Patient with VCAR33 (ALLO) and Provides Corporate Update
Vor Bio Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
Vor Bio Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
Vor Bio to Participate in the JMP Securities Hematology and Oncology Summit
Vor Bio Presents Positive Data Update on Trem-cel at HSCT² Conference
Vor Bio Reports Third Quarter 2023 Financial Results and Provides Company Update
Vor Bio Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
Vor Bio to Participate in Upcoming Investor Conferences
Source: https://incomestatements.info
Category: Stock Reports